Intravascular Access of COVID-19 Patient Under Personal Protective Equipment

L

Lazarski University

Status

Completed

Conditions

Emergencies
Cardiac Arrest

Treatments

Device: Intravenous access
Device: Intraosseous access

Study type

Interventional

Funder types

Other

Identifiers

NCT04366297
IO_PPE_MS_1

Details and patient eligibility

About

The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.

Enrollment

41 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • paramedic
  • consent voluntary participation in the study
  • none experience in resuscitation with personal protective equipment

Exclusion criteria

refusal to participate in the study

Trial design

41 participants in 2 patient groups

Standard of Care (Intravenous Cannula)
Experimental group
Description:
obtaining intravascular access using a ready standard intravenous cannula
Treatment:
Device: Intravenous access
IO access using NIO® set
Experimental group
Description:
receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
Treatment:
Device: Intraosseous access

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems